Many cancer-treating compounds used in chemotherapies, the so-called antimitotics, target the mitotic spindle. Spindle defects in turn trigger activation of the SAC (spindle assembly checkpoint), a surveillance mechanism that transiently arrests cells in mitosis to provide the time for error correction. When the SAC is satisfied, it is silenced. However, after a variable amount of time, cells escape from the mitotic arrest, even if the SAC is not satisfied, through a process called adaptation or mitotic slippage. Adaptation weakens the killing properties of antimitotics, ultimately giving rise to resistant cancer cells. We summarize here the mechanisms underlying this process and propose a strategy to identify the factors involved using budding yeast as a model system. Inhibition of factors involved in SAC adaptation could have important therapeutic applications by potentiating the ability of antimitotics to cause cell death.
The SAC (spindle assembly checkpoint): a safety device against aneuploidy
Mitosis carries the intrinsic potential of generating genome instability by giving rise to daughter cells with unbalanced genetic material. A number of processes must be executed precisely and correctly to ensure proper chromosome segregation: a bipolar mitotic spindle must be assembled and sister chromatids must attach via their kinetochores to microtubules that associate with opposite poles of this spindle. Since the splitting of sister chromatids during anaphase is one of the major cell cycle points of no return, it is mandatory that all chromosomes are bipolarly attached to the mitotic spindle before anaphase. This task is overseen by the SAC, a ubiquitous safety device that ensures the fidelity of chromosome segregation during mitosis. In the presence of kinetochores that are either unattached to spindle fibres or mono-oriented with respect to spindle poles, the SAC sends an inhibitory signal that delays the onset of anaphase and mitotic exit until bipolar attachment is achieved, thus preventing aneuploidy occurrence (reviewed in [1, 2] ).
The players involved in SAC signalling are conserved throughout evolution. During the process of microtubule capture by kinetochores during prophase and prometaphase, the SAC proteins Bub3, Mad2 and Mad3/BubR1 form the MCC (mitotic checkpoint complex) that inhibits the activity of the Cdc20/APC (cell division cycle 20/anaphasepromoting complex) ubiquitin ligase, which is essential to target the anaphase inhibitor securin and cyclin B for degradation. By inhibiting Cdc20/APC, the SAC prevents sister chromatid separation and mitotic exit until all chromosomes reach a correct bipolar attachment to the mitotic spindle. Other SAC proteins, such as the Mad1, Bub1, Mps1 and Ipl1/AuroraB kinases amplify the signal and regulate the rate of MCC formation (reviewed in [2] ). Most SAC proteins accumulate at unattached kinetochores during prophase and prometaphase and from this location generate the 'wait anaphase' signal that leads to Cdc20/APC inhibition, possibly by accelerating the rate of MCC formation (reviewed in [3] ).
Once satisfied by the attainment of bipolar attachment on all chromosomes, the SAC is switched-off by a number of different mechanisms, allowing sister chromatid separation and cell-cycle progression. This coincides with the disappearance of SAC proteins from kinetochores. Two major mechanisms contribute to SAC switch-off in metazoans: (i) poleward transport of SAC proteins and spindly by the minus-end directed motor dynein/dynactin from kinetochores along microtubules [4] [5] [6] ; and (ii) SAC silencing by p31 comet , which turns down the ability of Mad2 to inhibit Cdc20/APC [7] [8] [9] [10] . In addition, there are conflicting reports as to whether nondegradative ubiquitylation of Cdc20 by APC is required for MCC disassembly and to extinguish SAC signalling [11] [12] [13] . Budding and fission yeast, which undergo a closed mitosis in the absence of nuclear envelope breakdown, lack nuclear dynein and a clear homologue of p31 comet . In these organisms the protein phosphatase PP1 was recently shown to silence the SAC independently of microtubules [14] [15] [16] . In addition, degradation of the SAC kinase Mps1 at the onset of anaphase has also been proposed as a mechanism to switch-off the checkpoint [17] . Summary of the possible destinies of a cell in which the SAC has been activated by a single unattached kinetochore. The cell-cycle delay imposed by the SAC is normally sufficient to establish a bipolar attachment on all chromosomes and ensure proper anaphase (SAC satisfied). Upon prolonged SAC activation, if errors are not corrected (SAC unsatisfied), the cell can either die in mitosis by apoptosis or slip out of mitosis. This unscheduled mitotic exit can in turn produce different outcomes: (i) drive the cell into the apoptotic pathway, (ii) lead to a stable G 1 arrest, or (iii) allow entry into a new cell cycle. The latter fate gives rise to aneuploid cells. In the case of treatment with antimitotics that depolymerize microtubules, cells slipping out of mitosis will be either aneuploid (if one or more kinetochores remain attached) or polyploid (if all kinetochores remain unattached).
Adaptation or mitotic slippage: the cell's response to prolonged SAC activation
In spite of its key role in maintaining genome stability, the mitotic delay imposed by the SAC is not permanent, but rather transient. For example, in the continuous presence of microtubule-depolymerizing drugs eukaryotic cells are unable to form proper kinetochore-microtubule connections and to satisfy the checkpoint, but nevertheless can undergo sister chromatid separation and exit mitosis. This process is commonly referred to as 'adaptation' or 'mitotic slippage' [18, 19] . Adaptation to the SAC is, so far, little studied, although premature adaptation to checkpoint signalling might be an important cause of genetic instability and aneuploidy, and have a major impact on cancer treatment [18, 19] . Many chemotherapeutic agents used in the clinic, such as taxanes and vinca alkaloids (the so called 'antimitotics'), inhibit spindle function in human cells and are widely used for the treatment of breast and ovarian cancers. Their therapeutic effectiveness relies on their impact on mitotic progression. In fact, their ability to protract mitotic arrest is thought to be a major factor in their cytotoxicity. After many hours of SAC-induced cell-cycle arrest, cancer cells either undergo apoptosis in mitosis, or exit mitosis by slippage into a tetraploid G 1 state, from which they either die, or arrest in G 1 , or initiate a new cell cycle (Figure 1 ) [18, 20, 21] . The development of resistance to antimitotics correlates with the failure to undergo apoptosis and with the ability of cells to ultimately escape mitosis and enter the next G 1 -phase as viable entities [20, 22, 23] . Although it is quite intuitive that adaptation in the presence of spindle damage can lead to aneuploidy and chromosomal instability, thereby contributing to increase malignancy, more surprising is the finding that escaping the mitotic arrest imposed by MAD2 overexpression, which does not perturb spindle dynamics, also leads to chromosome gains and losses, as well as chromosome breaks and bridges [24] . This in turn results in the induction of a wide variety of neoplasias, thus accounting for the observation that Mad2 is overexpressed in many human tumours [25] [26] [27] . Therefore mitotic slippage to SAC activation seriously harms genome stability, presumably by uncoupling cell-cycle progression and mitotic control.
Whether cells exit from mitosis upon long-term SAC activation through overriding the checkpoint signal or through SAC silencing remains an open question. Adaptation to the DNA-damage checkpoint, for instance, occurs with concomitant extinction of checkpoint signalling. However, the discovery of mutations (such as the cdc5-ad mutation in the budding yeast Polo kinase; [28, 29] ) specifically impairing adaptation to, but not recovery from, the DNA-damage checkpoint argues that adaptation is not only conceptually, but also mechanistically, different from checkpoint silencing. Since upon prolonged treatment with nocodazole (a microtubuledepolymerizing drug) SAC proteins are retained at kinetochores when cells resume cell-cycle progression, adaptation was proposed to occur through SAC signalling override [30] . However, more direct assays on the activity of Cdc20/APC when cells adapt might lead to different conclusions. In fact, since CDK (cyclin-dependent kinase) activity is required to sustain the SAC [31] [32] [33] and it decreases during adaptation (see below), it is possible that SAC signalling declines during mitotic slippage. In addition, in light of the involvement of microtubule-binding proteins, such as dynein and spindly, in stripping SAC proteins from kinetochores, it is possible that disruption of the mitotic spindle by nocodazole impairs this mechanism, thus accounting for the persistence of SAC proteins at unattached kinetochores during adaptation. Other ways to silence the SAC, e.g. through p31
comet , could contribute to adaptation under these conditions.
Recent studies have started to define the molecular mechanisms underlying mitotic slippage. Mitotic exit under these conditions is linked to a progressive decline in cyclinB/CDK activity that, after reaching a threshold level, drives cells out of mitosis [20, 30] . The decrease in CDK activity is accompanied by cyclin B degradation and, consistently, expression of nondegradable cyclin B delays mitotic slippage upon prolonged spindle disassembly. Therefore the mechanism for how cells escape mitosis in the presence of functional SAC has been proposed to rely on the inability of the SAC to inhibit all Cdc20/APCs inside the cell [30] . Indeed, it has been proposed that the SAC is unlikely to inhibit all Cdc20 within the cell, as this would hardly be reversible [34] . In addition, the APC was recently shown to be active during mitotic slippage [35] .
What is the destiny of adapting cells? Results obtained by treating cancer cells with a KSP (hsEg5, kinesin-5) inhibitor, which leads to a mitotic arrest with monopolar spindles, led to the proposal that persistent spindle damage causes apoptosis coupled to slippage to SAC activation [36] . However, data recently obtained through single-cell analysis rather than on cell populations, showed that cancer cells undergo two alternative and competing pathways after prolonged treatment to microtubule toxins: either they die by apoptosis or slip out of mitosis [20] . The latter destiny can obviously be detrimental for cancer treatment and is prone to generate cells resistant to antimitotic drugs [22] . Both the apoptotic and slippage pathways have thresholds, and the fate of the cell is dictated by which threshold is breached first. Most importantly, inhibiting the cell-death pathway by caspase inactivation channels cells to slip out of mitosis, whereas interfering with cyclin B degradation and mitotic exit channels cells into the apoptotic pathway [20] . The important implication of these results is that the efficacy of antimitotic agents could be markedly increased by inhibiting the factors involved in mitotic slippage, thus favouring cell death.
Factors influencing adaptation to the SAC: what we can learn from yeast genetics
Surprisingly little is known currently about the factors that influence cell fate upon prolonged exposure to antimitotic drugs.
By using budding yeast as a model system, we started to study the process of adaptation to the SAC upon treatment with microtubule poisons, or hyperactivation of the SAC in the absence of spindle damage through MAD2 overexpression. Both of these conditions temporarily arrest cells in mitosis for a few hours. Afterwards, however, cells slip out of mitosis and keep dividing [36a]. We find that essential regulators of mitotic exit, such as Cdc20 and the Polo kinase Cdc5, are necessary for mitotic slippage [36a], in agreement with the possibility that a fraction of Cdc20/APC remains active upon SAC activation and promotes cyclin B destruction until their CDK activity drops below a threshold level sufficient to drive cells out of mitosis. Similarly, Cdc20 inactivation by siRNA (small interfering RNA) was recently shown to delay degradation of APC substrate during adaptation to prolonged nocodazole treatment in human cells [35] . The finding that essential regulators of cyclin B proteolysis, i.e. Cdc20 and Cdc5, are necessary for adaptation in yeast, along with the older proposal that inhibitory phosphorylation of cyclin B/CDKs accelerates adaptation to prolonged SAC activation [37] , suggests that inactivation of mitotic CDK is the driving force for mitotic slippage. Thus the molecular bases for adaptation to chronic SAC activation might be conserved in all eukaryotic cells, which makes budding yeast a good model system to identify factors influencing the rate of adaptation.
We designed a genetic screen to find yeast mutants defective in adaptation to the SAC. By searching for mutants delaying mitotic exit upon MAD2 overexpression, we have implicated the conserved RSC (chromatin structure remodelling) complex in the regulation of mitotic exit and adaptation to the spindle checkpoint [36a]. We find that it does so by controlling the protein phosphatase Cdc14, which is essential for mitotic exit, by promoting cyclin B degradation and accumulation of the cyclinB/CDK inhibitor Sic1 [38] . The yeast Cdc14 phosphatase is activated through its release from the nucleolus, where it is sequestered throughout most of the cell cycle by binding to its inhibitor Net1/Cfi1 as part of the chromatin-bound RENT (regulator of nucleolar silencing and telophase exit) complex [39, 40] . Two pathways contribute to the full activation of Cdc14: the FEAR (fourteen early anaphase release) and the MEN (mitotic exit network). By promoting a first wave of partial Cdc14 release from the nucleolus in early anaphase, the FEAR allows full activation of the MEN that leads to complete release of Cdc14 in the nucleus and cytoplasm, thereby triggering cyclin B proteolysis and mitotic exit [41] . Importantly, whereas MEN inhibition causes a cell-cycle arrest in telophase, FEAR inactivation only moderately delays mitotic exit [42] . We find that the RSC complex impinges specifically on the first wave of Cdc14 nucleolar release, which, although dispensable for mitotic exit under unperturbed conditions, becomes particularly important for mitotic slippage to SAC activation [36a]. Interestingly, the cdc5-ad mutation that delays adaptation to the DNA-damage checkpoint was proposed to be defective in the FEAR network [28] , raising the possibility that similar mechanisms underly adaptation to different checkpoints. Besides the different mitotic processes in which it has previously been implicated, the RSC complex has been involved in the detection of double-strand breaks and their repair [43] [44] [45] [46] [47] . It will be interesting to analyse its possible involvement also in the adaptation to the DNA-damage checkpoint.
Importantly, RSC mutants not only remain arrested in mitosis for longer times upon MAD2 overexpression or treatment with microtubule-depolymerizing drugs, but they also die under these conditions [36a]. We are currently investigating whether these cells die due to apoptosis or to other reasons. Nonetheless, these data suggest that the response to chronic SAC activation might follow the same general rules in budding yeast and mammalian cells and that impairing adaptation could commit cells to death, which has obvious clinical implications. In addition, based on our findings we propose that genetic screens using MAD2-overexpressing cells are excellent tools to discover novel finetuning regulators of mitotic exit and adaptation to the SAC.
In conclusion, discovering the factors that influence the rate of adaptation to prolonged SAC activation will be an important challenge in cancer research and promises to identify novel targets for therapeutic strategies. Combining inhibition of these proteins with conventional antimitotic agents could prevent adaptation and potentiate cell death. In addition, it would allow use of lower doses of antimitotics in chemotherapy, thus decreasing their neurotoxicity.
Strikingly, mitotic exit has recently been proposed to be a better cancer therapeutic target than spindle assembly. Indeed, Cdc20 inhibition efficiently kills cancer cells, preventing mitotic slippage and providing more time for apoptosis [48] . Targeting essential regulators of mitotic exit during cancer treatment would have the drawback of also killing normally proliferating cells of the human body. Our finding that non-essential tuners of mitotic exit, such as the RSC complex, dramatically impair adaptation to SAC signalling opens important therapeutic perspectives that will be worth pursuing in the future.
